Immunobioengineering approaches towards combinatorial delivery of immune-modulators and antigens

Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines

Volumn , Issue , 2013, Pages 161-181

  Singh, Ankur ^a   Pradhan, Pallab ^b   Roy, Krishnendu ^b  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b The University of Texas at Austin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929568237     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-5380-2_8     Document Type: Chapter

References (117)

1. Hubbell JA, Thomas SN, Swartz MA (2009) Materials engineering for immunomodulation. Nature 462(7272):449-460
2. Zhao X et al (2005) Directed cell migration via chemoattractants released from degradable microspheres. Biomaterials 26(24):5048-5063
3. Hart DN (1997) Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 90(9):3245-3287
4. Viallard JF et al (1999) Th1 (IL-2, interferon-gamma (IFN-gamma)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 115(1):189-195
5. Borrow P et al (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 3(2):205-211
6. Rinaldo C et al (1995) High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 69(9):5838-5842
7. Malanchere-Bres E et al (2001) CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice. J Virol 75(14):6482-6491
8. Abbas AK, Murphy KM, Sher A (1996) Functional diversity of helper T lymphocytes. Nature 383(6603):787-793
9. Roy K et al (1999) Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 5(4):387-391
10. Wild JS, Sur S (2001) CpG oligonucleotide modulation of allergic inflammation. Allergy 56(5):365-376
11. Goodman JS et al (1998) DNA immunotherapeutics: new potential treatment modalities for allergic disease. Int Arch Allergy Immunol 116(3):177-187
12. Gurunathan S, Klinman DM, Seder RA (2000) DNA vaccines: immunology, application, and optimization. Annu Rev Immunol 18:927-974
13. Donnelly JJ, Ulmer JB (1999) DNA vaccines for viral diseases. Braz J Med Biol Res 32(2):215-222
14. Calarota S et al (1998) Cellular cytotoxic response induced by DNA vaccination in HIV-1- infected patients. Lancet 351(9112):1320-1325
15. O'Hagan D, Singh M, Ulmer J (2006) Microparticle-based technologies for vaccines. Methods 40:10-19
16. Kranzer K et al (2000) CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon- gamma production and up-regulation of CD69 via induction of antigen-presenting cellderived interferon type I and interleukin-12. Immunology 99(2):170-178
17. Shoda LK et al (2001) Immunostimulatory CpG-modified plasmid DNA enhances IL-12, TNF-alpha, and NO production by bovine macrophages. J Leukoc Biol 70(1):103-112
18. Heeg K, Zimmermann S (2000) CpG DNA as a Th1 trigger. Int Arch Allergy Immunol 121(2):87-97
19. Heeg K (2000) CpG DNA co-stimulates antigen-reactive T cells. Curr Top Microbiol Immunol 247:93-105
20. Davis HL (2000) Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol 247:171-183
21. McCluskie MJ, Weeratna RD, Davis HL (2000) The role of CpG in DNA vaccines. Springer Semin Immunopathol 22(1-2):125-132
22. Krieg AM, Davis HL (2001) Enhancing vaccines with immune stimulatory CpG DNA. Curr Opin Mol Ther 3(1):15-24
23. Manoj S, Babiuk LA, van Drunen Littel-van den Hurk S (2004) Approaches to enhance the efficacy of DNA vaccines. Crit Rev Clin Lab Sci 41(1):1-39
24. Boussif O et al (1995) A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci U S A 92(16):7297-7301
25. Neu M, Fischer D, Kissel T (2005) Recent advances in rational gene transfer vector design based on poly(ethylene imine) and its derivatives. J Gene Med 7(8):992-1009
26. de Chastellier C, Thilo L (1997) Phagosome maturation and fusion with lysosomes in relation to surface property and size of the phagocytic particle. Eur J Cell Biol 74(1):49-62
27. Jilek S, Merkle HP, Walter E (2005) DNA-loaded biodegradable microparticles as vaccine delivery systems and their interaction with dendritic cells. Adv Drug Deliv Rev 57(3):377-390
28. Wagner E, Ogris M, Zauner W (1998) Polylysine-based transfection systems utilizing receptor- mediated delivery. Adv Drug Deliv Rev 30(1-3):97-113
29. Nguyen D et al (2008) Polymeric materials for gene delivery and DNA vaccination. Adv Mater 20:1-21
30. Regnstrom K et al (2003) PEI-A potent, but not harmless, mucosal immuno-stimulator of mixed T-helper cell response and FasL-mediated cell death in mice. Gene Ther 10(18):1575-1583
31. Richardson SC, Kolbe HV, Duncan R (1999) Potential of low molecular mass chitosan as a DNA delivery system: biocompatibility, body distribution and ability to complex and protect DNA. Int J Pharm 178(2):231-243
32. Illum L et al (2001) Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 51(1-3):81-96
33. Li GP et al (2009) Induction of Th1-type immune response by chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen Der p 2 for oral vaccination in mice. Cell Mol Immunol 6(1):45-50
34. Hedley ML, Curley J, Urban R (1998) Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses. Nat Med 4(3):365-368
35. Klencke B et al (2002) Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. Clin Cancer Res 8(5):1028-1037
36. Mathiowitz E et al (1997) Biologically erodable microspheres as potential oral drug delivery systems. Nature 386(6623):410-414
37. Wang D et al (2004) Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. J Clin Virol 31(Suppl 1):S99-S106
38. Singh A et al (2008) Efficient modulation of T-cell response by dual-mode, single-carrier delivery of cytokine-targeted siRNA and DNA vaccine to antigen-presenting cells. Mol Ther 16(12):2011-2021
39. Little SR et al (2004) Poly-beta amino ester-containing microparticles enhance the activity of nonviral genetic vaccines. Proc Natl Acad Sci U S A 101(26):9534-9539
40. Hedley ML (2003) Formulations containing poly(lactide-co-glycolide) and plasmid DNA expression vectors. Expert Opin Biol Ther 3(6):903-910
41. Thiele L et al (2001) Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J Control Release 76(1-2):59-71
42. Thiele L, Merkle HP, Walter E (2003) Phagocytosis and phagosomal fate of surface-modified microparticles in dendritic cells and macrophages. Pharm Res 20(2):221-228
43. Kasturi SP et al (2011) Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470(7335):543-547
44. Singh M, Chakrapani A, O'Hagan D (2007) Nanoparticles and microparticles as vaccinedelivery systems. Expert Rev Vaccines 6(5):797-808
45. Vordermeier HM et al (1995) Synthetic delivery system for tuberculosis vaccines: immunological evaluation of the M. tuberculosis 38 kDa protein entrapped in biodegradable PLG microparticles. Vaccine 13(16):1576-1582
46. Luby TM et al (2004) Repeated immunization with plasmid DNA formulated in poly(lactideco- glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1. Clin Immunol 112(1):45-53
47. Jung T et al (2001) Tetanus toxoid loaded nanoparticles from sulfobutylated poly(vinyl alcohol)-graft-poly(lactide-co-glycolide): evaluation of antibody response after oral and nasal application in mice. Pharm Res 18(3):352-360
48. Newman KD, Samuel J, Kwon G (1998) Ovalbumin peptide encapsulated in poly( d , l lactic-co-glycolic acid) microspheres is capable of inducing a T helper type 1 immune response. J Control Release 54(1):49-59
49. Matzelle MM, Babensee JE (2004) Humoral immune responses to model antigen co-delivered with biomaterials used in tissue engineering. Biomaterials 25(2):295-304
50. Carcaboso AM et al (2004) Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles. Vaccine 22(11-12):1423-1432
51. Kazzaz J et al (2006) Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency. J Control Release 110(3):566-573
52. Diwan M, Tafaghodi M, Samuel J (2002) Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres. J Control Release 85(1-3):247-262
53. Tafaghodi M, Sajadi Tabassi SA, Jaafari MR (2006) Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN. Int J Pharm 319(1-2):37-43
54. Borges O et al (2008) Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur J Pharm Biopharm 69(2):405-416
55. O'Hagan DT, Singh M, Ulmer JB (2004) Microparticles for the delivery of DNA vaccines. Immunol Rev 199:191-200
56. Denis-Mize KS et al (2000) Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells. Gene Ther 7(24):2105-2112
57. Singh M, O'Hagan D (1999) Advances in vaccine adjuvants. Nat Biotechnol 17(11):1075-1081
58. Singh M et al (2001) Cationic microparticles are an effective delivery system for immune stimulatory cpG DNA. Pharm Res 18(10):1476-1479
59. Kasturi SP, Sachaphibulkij K, Roy K (2005) Covalent conjugation of polyethyleneimine on biodegradable microparticles for delivery of plasmid DNA vaccines. Biomaterials 26(32):6375-6385
60. Pai Kasturi S et al (2006) Prophylactic anti-tumor effects in a B cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles. J Control Release 113(3):261-270
61. Singh M et al (2000) Cationic microparticles: a potent delivery system for DNA vaccines. Proc Natl Acad Sci U S A 97(2):811-816
62. Luo Y et al (2003) Plasmid DNA encoding human carcinoembryonic antigen (CEA) adsorbed onto cationic microparticles induces protective immunity against colon cancer in CEAtransgenic mice. Vaccine 21(17-18):1938-1947
63. Mollenkopf HJ et al (2004) Enhanced protective efficacy of a tuberculosis DNA vaccine by adsorption onto cationic PLG microparticles. Vaccine 22(21-22):2690-2695
64. He X et al (2005) Augmented humoral and cellular immune responses to hepatitis B DNA vaccine adsorbed onto cationic microparticles. J Control Release 107(2):357-372
65. Oster CG et al (2005) Cationic microparticles consisting of poly(lactide-co-glycolide) and polyethylenimine as carriers systems for parental DNA vaccination. J Control Release 104(2):359-377
66. Jaganathan KS, Vyas SP (2006) Strong systemic and mucosal immune responses to surfacemodi fied PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine 24(19):4201-4211
67. Fay F et al (2010) Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials 31(14):4214-4222
68. Walter E, Merkle HP (2002) Microparticle-mediated transfection of non-phagocytic cells in vitro. J Drug Target 10(1):11-21
69. Kazzaz J et al(2000) Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1. J Control Release 67:347-356
70. Singh M et al (2004) Anionic microparticles are a potent delivery system for recombinant antigens from Neisseria meningitidis serotype B. J Pharm Sci 93(2):273-282
71. Wendorf J et al (2008) A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum Vaccin 4(1):44-49
72. Ataman-Onal Y et al (2006) Surfactant-free anionic PLA nanoparticles coated with HIV-1 p24 protein induced enhanced cellular and humoral immune responses in various animal models. J Control Release 112:175-185
73. O'Hagan DT, Valiante NM (2003) Recent advances in the discovery and delivery of vaccine adjuvants. Nat Rev Drug Discov 2(9):727-735
74. Singh M, O'Hagan DT (2002) Recent advances in vaccine adjuvants. Pharm Res 19(6):715-728
75. Zhao Z, Leong KW (1996) Controlled delivery of antigens and adjuvants in vaccine development. J Pharm Sci 85(12):1261-1270
76. O'Hagan DT, Ott GS, Van Nest G (1997) Recent advances in vaccine adjuvants: the development of MF59 emulsion and polymeric microparticles. Mol Med Today 3(2):69-75
77. Kenney RT, Edelman R (2003) Survey of human-use adjuvants. Expert Rev Vaccines 2(2):167-188
78. Relyveld EH, Bizzini B, Gupta RK (1998) Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids. Vaccine 16(9-10):1016-1023
79. Ulanova M et al (2001) The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism. Infect Immun 69(2):1151-1159
80. Mutwiri G et al (2008) Co-administration of polyphosphazenes with CpG oligodeoxynucleotides strongly enhances immune responses in mice immunized with Hepatitis B virus surface antigen. Vaccine 26(22):2680-2688
81. Woo SJ et al (2008) Co-administration of carcinoembryonic antigen and HIV TAT fusion protein with CpG-oligodeoxynucleotide induces potent antitumor immunity. Cancer Sci 99(5):1034-1039
82. Malyala P, O'Hagan DT, Singh M (2009) Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticles. Adv Drug Deliv Rev 61(3):218-225
83. Vandepapeliere P et al (2008) Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26(10):1375-1386
84. Tabata Y, Ikada Y (1987) Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. J Pharm Pharmacol 39(9):698-704
85. Evans JT et al (2003) Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529. Expert Rev Vaccines 2(2):219-229
86. Baldridge JR, Crane RT (1999) Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods 19(1):103-107
87. Mata-Haro V et al (2007) The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316(5831):1628-1632
88. Fries LF et al (1992) Liposomal malaria vaccine in humans: a safe and potent adjuvant strategy. Proc Natl Acad Sci U S A 89(1):358-362
89. Zhou F, Huang L (1993) Monophosphoryl lipid A enhances specific CTL induction by a soluble protein antigen entrapped in liposomes. Vaccine 11(11):1139-1144
90. Chong CS et al (2005) Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery. J Control Release 102(1):85-99
91. Thoelen S, De Clercq N, Tornieporth N (2001) A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine 19(17-19):2400-2403
92. Thoelen S et al (1998) Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine 16(7):708-714
93. Moore A, McCarthy L, Mills KH (1999) The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1. Vaccine 17(20-21):2517-2527
94. Reed SG et al (2003) Prospects for a better vaccine against tuberculosis. Tuberculosis (Edinb) 83(1-3):213-219
95. Krieg AM (2006) Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 5(6):471-484
96. Kwissa M, Kasturi SP, Pulendran B (2007) The science of adjuvants. Expert Rev Vaccines 6(5):673-684
97. Krishnamachari Y, Salem AK (2009) Innovative strategies for co-delivering antigens and CpG oligonucleotides. Adv Drug Deliv Rev 61(3):205-217
98. Roman M et al (1997) Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 3(8):849-854
99. Oumouna M et al (2005) Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine. J Virol 79(4):2024-2032
100. Oussoren C, Storm G (2001) Liposomes to target the lymphatics by subcutaneous administration. Adv Drug Deliv Rev 50(1-2):143-156
101. Malyala P et al (2008) The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm Sci 97(3):1155-1164
102. Zhang XQ et al (2007) Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother 30(5):469-478
103. Intra J et al (2008) Pulsatile release of biomolecules from polydimethylsiloxane (PDMS) chips with hydrolytically degradable seals. J Control Release 127(3):280-287
104. Singh M et al (2006) Polylactide-co-glycolide microparticles with surface adsorbed antigens as vaccine delivery systems. Curr Drug Deliv 3:115-120
105. Judge AD et al (2005) Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 23(4):457-462
106. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8(2):129-138
107. Alexopoulou L et al (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413(6857):732-738
108. Kariko K et al (2004) Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3. J Immunol 172(11):6545-6549
109. Liu G et al (2004) Small interference RNA modulation of IL-10 in human monocyte-derived dendritic cells enhances the Th1 response. Eur J Immunol 34(6):1680-1687
110. Hill JA et al (2003) Immune modulation by silencing IL-12 production in dendritic cells using small interfering RNA. J Immunol 171(2):691-696
111. Jain S, Yap WT, Irvine DJ (2005) Synthesis of protein-loaded hydrogel particles in an aqueous two-phase system for coincident antigen and CpG oligonucleotide delivery to antigenpresenting cells. Biomacromolecules 6(5):2590-2600
112. Ali OA et al (2009) Infection-mimicking materials to program dendritic cells in situ. Nat Mater 8(2):151-158
113. Roy K et al (2003) Gene delivery with in-situ crosslinking polymer networks generates longterm systemic protein expression. Mol Ther 7(3):401-408
114. Hori Y et al (2008) Injectable dendritic cell-carrying alginate gels for immunization and immunotherapy. Biomaterials 29(27):3671-3682
115. Hori Y, Winans AM, Irvine DJ (2009) Modular injectable matrices based on alginate solution/ microsphere mixtures that gel in situ and co-deliver immunomodulatory factors. Acta Biomater 5(4):969-982
116. Singh A, Suri S, Roy K (2009) In-situ crosslinking hydrogels for combinatorial delivery of chemokines and siRNA-DNA carrying microparticles to dendritic cells. Biomaterials 30(28):5187-5200
117. Nochi T et al (2010) Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 9(7):572-578